TrialStudy of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Trial details
- Registry ID
- NCT07516093
- Phase
- Phase 3
Drug research
NX-5948
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Bexobrutideg
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNCT07516093 | NRIX | Phase 3 | Recruiting | 2029-10Estimated |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)NCT07221500 | NRIX | Phase 2 | Recruiting | 2028-01Estimated |
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Trial details
- Registry ID
- NCT07221500
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |